Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Post by spazzmanon Aug 12, 2013 3:02pm

506 Views

Post# 21664386

Beacon Securities analyst BUY recommendation with a target price $1.00

ProMetic Life Sciences

By MPL Staff Writer

Beacon Securities analyst Doug Cooper continues to rate the shares of ProMetic Life Sciences (TSX-PLI, $0.52) a buy. His 12-month target price of $1.00 remains unchanged.

“To date, neither our revenue model or valuation work includes any contribution from ‘orphan drugs’ or its therapeutics segment,” the analyst says, “however, both of these initiatives appear to be on the cusp of adding significant value.”

In fact, Mr. Cooper adds, orphan drug designation for the company’s drug plasminogen (a drug for the treatment of hypoplasminogenemia, or type I plasminogen deficiency) could result in a $60 million drug from the soon to be commissioned Laval plant – revenue that could generate EPS of $0.10 on its own.

ProMetic Life Sciences Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of drug therapeutics and protein technologies.

Bullboard Posts

How one company is disrupting PoC testing